- Company
- How about collaboration?
- by Kim, Jin-Gu Oct 13, 2022 06:09am
- 4th largest population in the world, the advantage of clinical performance. Indonesia is emerging as a new market for the Korean pharmaceutical bio industry. In addition to the potential of being the world's fourth-largest population, the pharmaceutical market seems to be expanding rapidly as national income has recently increased overall.
- Company
- Dupixent's child benefit expands after over 1 1/2 yrs
- by Eo, Yun-Ho Oct 13, 2022 06:08am
- Discussions on expanding insurance benefits for children and adolescents of Dupixent, a treatment for atopic dermatitis, have been slow. According to related industries, Sanofi-Aventis Korea's Dupixent 200mg passed the Drug Benefit Standards Subcommittee in May, but has yet to be submitted to the Drug Benefit Evaluation Committee. The drug w
- Company
- Status of antidiabetic SGLT-2 inhibitors rise with use in HF
- by Oct 13, 2022 06:08am
- SGLT-2 inhibitors that were initially released as a diabetes treatment have expanded their scope and risen as a representative heart drug. In addition to Heart Failure with reduced EF (HFrEF) and Heart Failure with mildly reduced EF (HFmrEF), SGLT-2 inhibitors have also demonstrated an effect in Heart Failure with Preserved Ejection Fraction (HF
- Company
- The third PD-1 immuno-cancer drug is about to enter Korea
- by Eo, Yun-Ho Oct 12, 2022 05:50am
- It is predicted that additional immuno-cancer drugs with PD-1 inhibitory mechanisms will enter the domestic market. According to related industries, the Ministry of Food and Drug Safety is reviewing the final approval of PD-1 inhibitor Jemperli, which GSK Korea submitted an application for permission in March. Approval is possible as early a
- Company
- Reimb for Ilaris unclear... benefits 13 patients in Korea
- by Eo, Yun-Ho Oct 11, 2022 05:51am
- As well expected, no progress has been made in reimbursing ‘Ilaris,’ an orphan drug that affects 13 patients in Korea. According to industry sources, reimbursement discussions for Ilaris (canakinumab), Novartis Korea’s Hereditary recurrent fever syndrome treatment that the company applied for in the first half of the year is making slo
- Company
- Hemlibra, emerged as an issue of the National Audit Office
- by Nho, Byung Chul Oct 11, 2022 05:50am
- As the administration of non-antibody patients has been delayed for more than three years since Hemlibra, an innovative new drug for hemophilia A, is expected to emerge as a topic of the parliamentary audit. Representative Kang Sun-woo (Democratic Party of Korea), a member of the Health and Welfare Committee, will question the issue of the be
- Company
- Will the premium vaccine market rebound?
- by Kim, Jin-Gu Oct 11, 2022 05:50am
- Whether the premium vaccine market, which consists of vaccines used to prevent diseases like shingles, pneumococcal vaccines, etc., will be able to overcome the COVID-19 crisis and make a rebound is gaining attention. Expectations of market recovery are rising in the pharma and bio-industry with the eased resurgence of COVID-19, cautious expe
- Company
- Emergency Contraception (EC) monopolized by Hyundai
- by Oct 11, 2022 05:50am
- As generics enter the Emergency Contraception (EC) market, which is dominated by Hyundai Pharmaceutical, a maximum of five-way race is expected. Generics that avoided patents led by GL Pharma predicted full-scale sales this month. According to the pharmaceutical industry on the 8th, Arlico Pharmaceutical, The U, GL Pharma, and Kwangdong Pharm
- Company
- The second CGRP migraine drug Ajovy's benefit is listed
- by Eo, Yun-Ho Oct 11, 2022 05:50am
- According to related industries, Handok Teva has begun negotiations with the HIRA on the drug price of Ajovy, a target migraine treatment for Calcitoningenene-related peptide (CGRP). Ajovy passed the HIRA Drug Benefit Evaluation Committee last month. Ajovy's drug price is expected to be negotiated as its competitive drug and first item, Emga
- Company
- Only 2 out of 10 are prescribed monotherapy for diabetes
- by Kim, Jin-Gu Oct 7, 2022 06:04am
- The use of combination therapies in diabetes has been increasing further. Already, 8 of 10 patients are prescribed two or more drugs at once. In particular, the triple therapy combination regimen seems to be rapidly establishing its presence in the field. By ingredient, DPP-4 inhibitor class drugs are still showing strength, but their growth
